Form 4: Elanco Animal Health CEO Jeffrey Simmons Reports Acquisition of Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, reported the acquisition of deferred stock units, convertible to common stock, as per a recent SEC Form 4 filing.

Summary

• On February 23, 2024, Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired 169.1655 deferred stock units.
• These deferred stock units represent the right to receive one share of Elanco's common stock or the cash equivalent.
• The price of the derivative security is $16.37.
• Following the reported transaction, Simmons beneficially owns 703.0812 derivative securities.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, according to the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns management interests with shareholders.

Future Outlook

The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

This filing reflects standard executive compensation practices within publicly traded companies, where stock-based compensation is used to align management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of deferred stock units by the CEO aligns his interests with those of shareholders, potentially driving long-term value creation.

Key Dates